Company intelligence / Profile preview

X-Pert-Med

Ownership: Private
Development stage: Phase 2

Overview

X-Pert-Med GmbH has completed several Phase 1 clinical trials investigating the effects of small molecules such as etoricoxib, ibuprofen, hydrocortisone, and strontium chloride hexahydrate on inflammation and pain in healthy volunteers. The studies focused on UVB/UVR-induced erythema/pain models as well as exercise-induced muscle pain. No later-stage or commercial programs are reported.

Therapeutic areas: DermatologyNeurology
Modalities: Small moleculeChemicalTopical drugOral drug
Industry: Contract Research Organization

Drug pipeline

3 assets

etoricoxib

Phase 1

Indications: Muscle pain

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on X-Pert-Med.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on X-Pert-Med.

Explore the full profile